Get to know our clinical trials
Trial of MK-7684A in participants with relapsed or refractory hematologic malignancies
THIS TRIAL IS BEING DONE TO: ¿ ASSESS THE SAFETY OF MK-7684A ¿ FIND OUT HOW WELL YOUR BODY TOLERATES MK-7684A ¿ FIND OUT HOW WELL MK-7684A WORKS ¿ DETERMINE WHAT HAPPENS AS MK-7684A PASSES THROUGH YOUR BODY ¿ SEE IF PARTICIPANTS WHO RECEIVE MK-7684A LIVE LONGER ¿ SEE IF PEOPLE WHO RECEIVE MK-7684A HAVE A BETTER QUALITY OF LIFE
Technical Summary
- PHASE 2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-7684A (COFORMULATION OF MK-7684 [VIBOSTOLIMAB] WITH MK-3475 [PEMBROLIZUMAB]) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. IMMUNOTHERAPY
- Code EudraCT: 2021-001700-15
- Protocol number: MK-7684A-004
- Promoter: Merck Sharp & Dohme, S.A.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.